Menopausal women gaining weight in their abdominal area is such a common phenomenon that it even has a nickname: menopause belly fat or menopause tummy. Declining estrogen is one factor that contributes to menopause belly
Notably, this study included broad range of GLP-1 drugs, including much older GLP-1s that have far lower anti-obesity, anti-craving, and anti-addictive effects: abiglutide (Eperzan, Tanzeum), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin, Lyxumia), semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro) Its possible that the associations that were found would be even stronger if the study had looked exclusively at semaglutide and tirzepatide, which are the current best-in-class options for weight loss
Additionally, your provider may recommend biomarker reassessment at this time to identify any emerging metabolic concerns that warrant intervention
A lot of people get caught up in the numbers and forget that tolerability matters just as much
10 (52.6%)), and altered sulfur pathways